Monday, October 28, 2024 5:35:22 PM
Investor082,
An approved product in the bag for a pre revenue biotech adds baseline value due to greatly reduced risk. Selling after a risk off event but before value added news of a significant nature expected beyond this, that might occur at anytime, increases the opportunity for “smart money” to get in cheap after the risk carried by others so long is removed.
Personally speaking, I won’t be trying to time the news but might trade some shares in a Roth account if there is a massive spike from the right kind of news that creates a temporary strongly overbought situation and buying back in lower looks like a good opportunity being created. I said before that I might do this when a strong long term uptrend is created first. Best wishes.
An approved product in the bag for a pre revenue biotech adds baseline value due to greatly reduced risk. Selling after a risk off event but before value added news of a significant nature expected beyond this, that might occur at anytime, increases the opportunity for “smart money” to get in cheap after the risk carried by others so long is removed.
Personally speaking, I won’t be trying to time the news but might trade some shares in a Roth account if there is a massive spike from the right kind of news that creates a temporary strongly overbought situation and buying back in lower looks like a good opportunity being created. I said before that I might do this when a strong long term uptrend is created first. Best wishes.
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
